PEG 3350 is named as an intervention in 2 current clinical trials in our Canada and Israel registers. None are recruiting at the moment. The most common phase is Phase 2/3. The sponsor with the most trials is Hamilton Health Sciences Corporation (1). The most-studied condition is Constipation - Functional.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Senna vs. Polyethylene Glycol 3350 for the Treatment of Retentive Encopresis in Children
NCT07604025 · ClinicalTrials.gov ↗ · Encopresis With Constipation and Overflow Incontinence
|
Phase EARLY_PHASE1 | Not yet open | Shaare Zedek Medical Center | Israel |
|
A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation
NCT06836024 · ClinicalTrials.gov ↗ · Constipation - Functional, Constipation, Constipation Aggravated
|
Phase 2/3 | Not yet open | Hamilton Health Sciences Corporation | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Hamilton Health Sciences Corporation | 1 |
| Shaare Zedek Medical Center | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Israel | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Canada and Israel registers name PEG 3350 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Hamilton Health Sciences Corporation (1) and Shaare Zedek Medical Center (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how PEG 3350 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PEG 3350 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PEG 3350 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.